Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. SORIATANE (acitrétine)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

SORIATANE (acitrétine)

Medicine - Posted on Jan 15 2018 - Updated on Jun 12 2019
Active substance (DCI)
  • acitrétine
history (4)
  • 12/13/17

    SORIATANE (acitrétine)

    Maintien du remboursement dans les mêmes conditions.
    icône flèche
  • 10/15/14

    SORIATANE (acitretin), retinoid

    Improve compliance with the measures for prescribing and dispensing in women of childbearing potential to prevent pregnancy ...
    icône flèche
  • 3/14/07

    SORIATANE (acitrétine)

    Maintien du remboursement dans les mêmes conditions
    icône flèche
  • 4/3/02

    SORIATANE (acitrétine)

    Maintien du remboursement dans les mêmes conditions
    icône flèche
Technical information
ATC code
  • D05BB02
Manufacturer
ARROW GÉNÉRIQUES
Presentation

SORIATANE 10 mg, gélule (code CIS : 60292349) plaquette(s) de 30 gélules - Code CIP : 3400933126391

SORIATANE 25 mg, gélule (code CIS : 64225999) plaquette(s) de 30 gélules - Code CIP : 3400933126742

All our publications
    Autoimmune diseases Drug therapy Skin and connective tissue diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
qN3K97dL9rfWfNZk